Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0HENYV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | B31?H3L3 |
|||||
| Synonyms |
B31?H3L3
Click to Show/Hide
|
|||||
| Antigen Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN119371541A B31-H3L3-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
15.37%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 2mg/kg B31-H3L3-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
16.05%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 0.4mg/kg B31-H3L3-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
34.96%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 2.5 (D15)/3.5 (D29)mpk B31-H3L3-MMAE (Q2WƦ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
43.98%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (A549) tumor cells,and treatment with 10mpk (mg/kg)B31-H3L3-MMAE (BIWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 48.
|
||||
| In Vivo Model | A549 xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
60.47%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 2.5mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
79.24%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 10mpk (mg/kg) B31-H3L3-MMAE (single dose)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
79.79%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NSG),by subcutaneous injection of 1x106 (MDA-MB-231) tumor cells,and treatment with 5mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
85.53%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 10mg/kg B31-H3L3-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.52%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (NCI-N87) tumor cells,and treatment with 5mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
95.44%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 10mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
96.60%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NSG),by subcutaneous injection of 1x106 (MDA-MB-231) tumor cells,and treatment with 10mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.02%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 5mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
99.31%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (NCI-N87) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
100%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 10mpk (mg/kg) B31-H3L3-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
100%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 10mpk (mg/kg) B31-H3L3-MMAE (single dose)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
15.24 nM
|
High ROR1 expression (ROR1 +++) | ||
| Method Description |
MDA-MB-468 cell line was plated at 2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
38.24 nM
|
|||
| Method Description |
Jeko-1 cell line was plated at 1×105cell/mL, 90uL/well,12 hours later,ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
58.45 nM
|
|||
| Method Description |
HT-29 cell line (1×104cell/mL,100uL/well) , the ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added 12 hours later, and incubated for 96h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
117.3 nM
|
|||
| Method Description |
NCI-H1944 cell line was plated at 1.2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
280.6 nM
|
Moderate ROR1 expression (ROR1++) | ||
| Method Description |
A549 at 1×104cell/mL,100uL/well, 12 hours later,ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added and incubated for 72h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||